CHRS

Coherus Oncology, Inc.
CAPPED RATING

Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.

Coherus Oncology, Inc. (CHRS) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Momentum (D+). The rating has held at C+ for 10 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.0
EV / EBITDA -0.5
Rev Growth YoY 23.4%
Gross Margin 69.8%
Price Return 3M -45.2%
Price Return 12M -52.2%
Catalyst Signal 0.00
Market Cap $99.0M
TTM Revenue $53.6M
Price / Sales 1.8
ROE -275.2%

Historical Factor Score Progression

Held C+ for 10 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) B- (3.1) C+ (2.8) D+ (1.5) C+ (2.6) C+ (2.6)
2026-11-04 B- (3.0) B (3.3) B- (3.0) D (1.4) C+ (2.7) C+ (2.7)
2026-10-28 B- (3.0) B (3.3) B- (3.0) D+ (1.7) C+ (2.7) C+ (2.7)
2026-10-21 B- (3.0) B (3.3) B- (3.0) D+ (1.8) C+ (2.6) C+ (2.7)
2026-10-14 B- (3.0) B (3.3) B- (3.0) C- (2.0) C+ (2.6) C+ (2.8)
Page 1 of 6